E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Guillermo Montalban-Bravo,Rashmi Kanagal-Shamanna,Faezeh Darbaniyan,Maria Tariq Siddiqui,Koji Sasaki,Yue Wei,Hui Yang,Kelly S. Chien,Kiran Naqvi,Elias Jabbour,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Farhad Ravandi,Naveen Pemmaraju,Prithviraj Bose,Srdan Verstovsek,Sherry Pierce,Carlos E. Bueso-Ramos,Keyur P. Patel,Kim Anh Do,Hagop M. Kantarjian,Guillermo Garcia-Manero +22 more
Journal ArticleDOI
Treatment with Nilotinib for Patients with Chronic Myeloid Leukemia (CML) Who Failed Prior Therapy with Imatinib and Dasatinib.
TL;DR: Nilotinib has modest activity in patients with CML resistant to both imatinib and dasatinib, and is concluded to be in complete molecular remission post allogeneic stem cell transplantation.
Journal ArticleDOI
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Guillermo Garcia-Manero,Ellen K. Ritchie,Katherine Walsh,Michael R. Savona,Michael R. Savona,Hagop M. Kantarjian,Patricia Kropf,Casey O'Connell,Raoul Tibes,Naval Daver,Elias Jabbour,Scott D. Lunin,Todd L. Rosenblat,Karen W.L. Yee,Wendy Stock,Elizabeth A. Griffiths,Joseph R. Mace,Nikolai A. Podoltsev,Jesus G. Berdeja,Jean Pierre J. Issa,Sue Naim,Yong Hao,Mohammad Azab,Gail J. Roboz +23 more
TL;DR: Efficacy was evaluated by the clinical responses of CR, PR, marrow CR (mCR), and Hematological Improvement (HI) based on the International Working Group Criteria 2006, as well as transfusion-independence, and overall survival (OS).
Journal ArticleDOI
Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials
Musa Yilmaz,Hagop M. Kantarjian,Elias Jabbour,Susan O'Brien,Gautam Borthakur,Srdan Verstovsek,Guillermo Garcia-Manero,Farhad Ravandi,Jan A. Burger,Sherry Pierce,Alfonso Quintás-Cardama,Jorge E. Cortes +11 more
TL;DR: It is suggested that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in aclinical trial provided they are followed with the same rigor.
Journal ArticleDOI
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation
Maria Khouri,Elias Jabbour,Alison M. Gulbis,Francesco Turturro,Celina Ledesma,Martin Korbling,Barry I. Samuels,Sairah Ahmed,Amin M. Alousi,Stefan O. Ciurea,David Marin,Krina K. Patel,Uday R. Popat,Carlos E. Bueso-Ramos,Roland L. Bassett,Issa F. Khouri +15 more
TL;DR: It is suggested that treatments other than lenalidomide are needed for persistent CLL after allogeneic stem cell transplantation and in patients in complete remission who were not randomized.